Cargando…

Natural Compounds for Alzheimer’s Disease Therapy: A Systematic Review of Preclinical and Clinical Studies

Alzheimer’s Disease (AD) is a neurodegenerative disorder related with the increase of age and it is the main cause of dementia in the world. AD affects cognitive functions, such as memory, with an intensity that leads to several functional losses. The continuous increase of AD incidence demands for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andrade, Stephanie, Ramalho, Maria João, Loureiro, Joana Angélica, Pereira, Maria do Carmo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539304/ https://www.ncbi.nlm.nih.gov/pubmed/31083327 http://dx.doi.org/10.3390/ijms20092313

Ejemplares similares

Interaction of Bortezomib with Cell Membranes Regulates Its Toxicity and Resistance to Therapy
por: Ramalho, Maria João, et al.
Publicado: (2022)

Therapeutic Potential of Natural Compounds in Neurodegenerative Diseases: Insights from Clinical Trials
por: Andrade, Stéphanie, et al.
Publicado: (2023)

Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment
por: Andrade, Stephanie, et al.
Publicado: (2018)

Polymeric Nanoparticles-Loaded Hydrogels for Biomedical Applications: A Systematic Review on In Vivo Findings
por: Nunes, Débora, et al.
Publicado: (2022)

Transferrin Receptor-Targeted Nanocarriers: Overcoming Barriers to Treat Glioblastoma
por: Ramalho, Maria João, et al.
Publicado: (2022)

Transferrin-Conjugated PLGA Nanoparticles for Co-Delivery of Temozolomide and Bortezomib to Glioblastoma Cells
por: Ramalho, Maria João, et al.
Publicado: (2023)

Vine Cane Compounds to Prevent Skin Cells Aging through Solid Lipid Nanoparticles
por: Pereira, Adriana, et al.
Publicado: (2022)

Factorial Design as a Tool for the Optimization of PLGA Nanoparticles for the Co-Delivery of Temozolomide and O6-Benzylguanine
por: Ramalho, Maria João, et al.
Publicado: (2019)

Fluorinated Molecules and Nanotechnology: Future ‘Avengers’ against the Alzheimer’s Disease?
por: Dabur, Meghna, et al.
Publicado: (2020)

PLGA Based Drug Carrier and Pharmaceutical Applications: The Most Recent Advances
por: Loureiro, Joana Angélica, et al.
Publicado: (2020)

Transferrin-Functionalized Liposomes for the Delivery of Gallic Acid: A Therapeutic Approach for Alzheimer’s Disease
por: Andrade, Stéphanie, et al.
Publicado: (2022)

Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
por: Nunes, Débora, et al.
Publicado: (2022)

(De)stabilization of Alpha-Synuclein Fibrillary Aggregation by Charged and Uncharged Surfactants
por: Loureiro, Joana Angélica, et al.
Publicado: (2021)

PLGA nanoparticles as a platform for vitamin D-based cancer therapy
por: Ramalho, Maria J, et al.
Publicado: (2015)

Resveratrol and Grape Extract-loaded Solid Lipid Nanoparticles for the Treatment of Alzheimer’s Disease
por: Loureiro, Joana A., et al.
Publicado: (2017)

Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence
por: Lin, Shian‐Ren, et al.
Publicado: (2019)

Radiosynthesis, Preclinical, and Clinical Positron Emission Tomography Studies of Carbon-11 Labeled Endogenous and Natural Exogenous Compounds
por: Shegani, Antonio, et al.
Publicado: (2022)

Lipid Nanoparticles Containing Mixtures of Antioxidants to Improve Skin Care and Cancer Prevention
por: Gonçalves, Catarina, et al.
Publicado: (2021)

Correction to “Radiosynthesis, Preclinical and Clinical Positron Emission Tomography Studies of Carbon-11 Labeled Endogenous and Natural Exogenous Compounds”
por: Shegani, Antonio, et al.
Publicado: (2023)

Natural Compounds in Glioblastoma Therapy: Preclinical Insights, Mechanistic Pathways, and Outlook
por: Zhai, Kevin, et al.
Publicado: (2021)

Multi-Dose Intravenous Administration of Neutral and Cationic Liposomes in Mice: An Extensive Toxicity Study
por: Andrade, Stéphanie, et al.
Publicado: (2022)

Immunoliposomes doubly targeted to transferrin receptor and to α-synuclein
por: Loureiro, Joana A, et al.
Publicado: (2015)

A New Perspective for the Treatment of Alzheimer’s Disease: Exosome-like Liposomes to Deliver Natural Compounds and RNA Therapies
por: Ribeiro, Joana, et al.
Publicado: (2023)

Impact of Natural Compounds on Neurodegenerative Disorders: From Preclinical to Pharmacotherapeutics
por: Sharifi-Rad, Mehdi, et al.
Publicado: (2020)

Preclinical Evidence and Possible Mechanisms of Extracts or Compounds from Cistanches for Alzheimer’s Disease
por: Zhou, Xiao-Li, et al.
Publicado: (2019)

Antiseizure Medications in Alzheimer’s Disease from Preclinical to Clinical Evidence
por: Bosco, Francesca, et al.
Publicado: (2023)

Fighting Methicillin-Resistant Staphylococcus aureus with Targeted Nanoparticles
por: Andrade, Stéphanie, et al.
Publicado: (2023)

Influence of temperature and light on total phenolic compounds during natural orange juice storage
por: Capitão, C., et al.
Publicado: (2021)

Determining clinically meaningful decline in preclinical Alzheimer disease
por: Insel, Philip S., et al.
Publicado: (2019)

Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pandemic
por: Khalifa, Shaden A.M., et al.
Publicado: (2021)

Preclinical and Clinical Antioxidant Effects of Natural Compounds against Oxidative Stress-Induced Epigenetic Instability in Tumor Cells
por: Bouyahya, Abdelhakim, et al.
Publicado: (2021)

Clinical and Preclinical Systematic Review of Panax ginseng C. A. Mey and Its Compounds for Fatigue
por: Jin, Ting-Yu, et al.
Publicado: (2020)

Nanomaterials towards Biosensing of Alzheimer’s Disease Biomarkers
por: Carneiro, Pedro, et al.
Publicado: (2019)

Flavonoids as Therapeutic Agents in Alzheimer's and Parkinson's Diseases: A Systematic Review of Preclinical Evidences
por: de Andrade Teles, Roxana Braga, et al.
Publicado: (2018)

Natural Plant Extracts and Compounds for Rheumatoid Arthritis Therapy
por: Zhao, Xiangyu, et al.
Publicado: (2021)

Preclinical and clinical issues in Alzheimer's disease drug research and development
por: Mancuso, Cesare, et al.
Publicado: (2014)

Recruiting to preclinical Alzheimer's disease clinical trials through registries
por: Grill, Joshua D.
Publicado: (2017)

Clinical and Preclinical Studies of Fermented Foods and Their Effects on Alzheimer’s Disease
por: Kumar, Muganti Rajah, et al.
Publicado: (2022)

Role of Natural Compounds and Target Enzymes in the Treatment of Alzheimer’s Disease
por: Wang, Shanshan, et al.
Publicado: (2022)

Forest Biomass as a Promising Source of Bioactive Essential Oil and Phenolic Compounds for Alzheimer’s Disease Therapy
por: Moreira, Patrícia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3lccdhnkskic01s3bcolph0l1g